Product Description
S-777469 is an orally available CB2 agonist as an antipruritic agent. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22444677/)
Mechanisms of Action: CB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: